Pegasta Pegylated r human granulocyte colony stimulating factor injection 6 mg

Send Inquiry

Request To Call Back

Pegasta Pegylated r human granulocyte colony stimulating factor injection 6 mg

Name: Pegasta Pegylated r human granulocyte colony stimulating factor injection 6 mg
Brand: ONCOTRUST
Price: 1500.0 INR
Availability: InStock

Price 1500.0 INR/ Piece

Get a Price/Quote

MOQ : 30 Pieces

Pegasta Pegylated r human granulocyte colony stimulating factor injection 6 mg Specification

Salt Composition
60mg

Dosage Form
60

Indication
cancer

Origin
india

Enzyme Types
Emulsifiers

Feature
Other

Ingredients
Other

Application
Other

Ph Level
5

Temperature Needed For Fermentation
2C to 8C Celsius (oC)

Physical Color/Texture
Other

Fermentation Smell
Normal Smell

Enzymatic Activity
1

Storage Instructions
2-8c

Shelf Life
24 Hours

Pegasta Pegylated r human granulocyte colony stimulating factor injection 6 mg Trade Information

Minimum Order Quantity
30 Pieces

Delivery Time
24 Hours

About Pegasta Pegylated r human granulocyte colony stimulating factor injection 6 mg

Fegasta Injection contains Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (Peg-G-CSF) 6 mg, used to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients undergoing chemotherapy. It helps stimulate the production of neutrophils, thereby strengthening the immune system and reducing the risk of infections.

Key Benefits:

Promotes rapid recovery of neutrophil count
Reduces infection risk during cancer chemotherapy
Long-acting formulation once-per-cycle dosing
Improves patient compliance and treatment outcomes

Composition:

Pegylated Recombinant Human Granulocyte Colony Stimulating Factor 6 mg

Indications:

Chemotherapy-induced neutropenia
Prevention of febrile neutropenia in cancer patients

Dosage & Administration:

Administered as a subcutaneous injection
Dosage as prescribed by the treating physician

Storage Instructions:

Store at 2C to 8C (Refrigerated)
Do not freeze
Protect from light

Packaging:

Pre-filled syringe / vial (as per availability)

Safety Information:

For prescription use only
To be used under medical supervision
Not recommended for self-medication

Advanced Support for Cancer Care

Pegasta Pegylated r human granulocyte colony stimulating factor injection is specifically formulated to help cancer patients manage neutropenia by boosting white blood cell production. Its scientifically engineered formulation, with precisely measured ingredients and pH, ensures optimal patient safety and effectiveness during cancer treatments such as chemotherapy or radiotherapy.

Careful Handling and Storage

To preserve the efficacy of Pegasta injection, it is crucial to maintain its storage at a strict temperature range of 2C to 8C. The product has a shelf life of 24 hours once opened, emphasizing the need for timely use. Proper storage not only maintains potency but also minimizes risks of contamination or degradation.

FAQ's of Pegasta Pegylated r human granulocyte colony stimulating factor injection 6 mg:

Q: How is Pegasta injection administered?

A: Pegasta Pegylated r human granulocyte colony stimulating factor injection is given by a healthcare professional, typically as a subcutaneous injection. The dosage and frequency will depend on the patient's medical condition and response to cancer therapy.

Q: What are the main benefits of using Pegasta for cancer patients?

A: Pegasta helps increase the body's white blood cell count, reducing the risk of infection during chemotherapy or radiotherapy, and aiding in the recovery of the immune system.

Q: When should this injection be used during cancer treatment?

A: Pegasta is usually administered after chemotherapy sessions to help restore white blood cell counts. The exact timing is determined by the treating oncologist based on individual patient needs.

Q: Where should Pegasta injection be stored before use?

A: Keep Pegasta refrigerated at 2C to 8C. Avoid freezing the product, as improper temperature can reduce its efficacy.

Q: What is involved in the manufacturing process of Pegasta?

A: Pegasta is produced in India using recombinant DNA technology, followed by fermentation at 2C to 8C and the inclusion of enzymatic emulsifiers to ensure stability and effectiveness of the final product.

Q: How long can Pegasta be used after opening?

A: This product must be used within 24 hours after opening, as its shelf life is limited to ensure maximum potency and safety.

Q: What makes Pegasta different from other similar injections?

A: Pegasta is distinguished by its specific enzyme composition, controlled pH, normal smell, and stringent storage requirements, all designed to enhance patient outcomes and product reliability.

Tell us about your requirement